325 related articles for article (PubMed ID: 21464590)
1. Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effects.
Lee YS; Kim SH; Cho JA; Kim CW
Exp Mol Med; 2011 May; 43(5):281-90. PubMed ID: 21464590
[TBL] [Abstract][Full Text] [Related]
2. Exosomes from CIITA-transfected CT26 cells enhance anti- tumor effects.
Fan W; Tian XD; Huang E; Zhang JJ
Asian Pac J Cancer Prev; 2013; 14(2):987-91. PubMed ID: 23621273
[TBL] [Abstract][Full Text] [Related]
3. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA.
Pan H; O'Brien TF; Wright G; Yang J; Shin J; Wright KL; Zhong XP
J Immunol; 2013 Jul; 191(2):699-707. PubMed ID: 23776173
[TBL] [Abstract][Full Text] [Related]
4. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
5. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
Accolla RS; Ramia E; Tedeschi A; Forlani G
Front Immunol; 2019; 10():1806. PubMed ID: 31417570
[TBL] [Abstract][Full Text] [Related]
6. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
Martin BK; Frelinger JG; Ting JP
J Immunol; 1999 Jun; 162(11):6663-70. PubMed ID: 10352284
[TBL] [Abstract][Full Text] [Related]
7. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.
Chen W; Wang J; Shao C; Liu S; Yu Y; Wang Q; Cao X
Eur J Immunol; 2006 Jun; 36(6):1598-607. PubMed ID: 16708399
[TBL] [Abstract][Full Text] [Related]
8. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
9.
Letendre C; Auger JP; Lemire P; Galbas T; Gottschalk M; Thibodeau J; Segura M
Front Immunol; 2018; 9():1199. PubMed ID: 29899744
[No Abstract] [Full Text] [Related]
10. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells.
Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C
J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519
[TBL] [Abstract][Full Text] [Related]
11. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
12. Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10.
O'Keefe GM; Nguyen VT; Benveniste EN
Eur J Immunol; 1999 Apr; 29(4):1275-85. PubMed ID: 10229095
[TBL] [Abstract][Full Text] [Related]
13. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
15. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models.
Cho JA; Lee YS; Kim SH; Ko JK; Kim CW
Cancer Lett; 2009 Mar; 275(2):256-65. PubMed ID: 19036499
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
17. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
18. Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis.
Waldburger JM; Palmer G; Seemayer C; Lamacchia C; Finckh A; Christofilopoulos P; Baeten D; Reith W; Gabay C
Arthritis Rheum; 2011 Nov; 63(11):3354-63. PubMed ID: 21739421
[TBL] [Abstract][Full Text] [Related]
19. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
[TBL] [Abstract][Full Text] [Related]
20. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]